<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atoltivimab, maftivimab, and odesivimab (United States: Available via manufacturer expanded access or public health distribution): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atoltivimab, maftivimab, and odesivimab (United States: Available via manufacturer expanded access or public health distribution): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Atoltivimab, maftivimab, and odesivimab (United States: Available via manufacturer expanded access or public health distribution): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="129813" href="/d/html/129813.html" rel="external">see "Atoltivimab, maftivimab, and odesivimab (United States: Available via manufacturer expanded access or public health distribution): Drug information"</a> and <a class="drug drug_patient" data-topicid="129869" href="/d/html/129869.html" rel="external">see "Atoltivimab, maftivimab, and odesivimab (United States: Available via manufacturer expanded access or public health distribution): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F54962412"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span>;</li>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block don drugH1Div" id="F54990597"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="798ca1a5-e33d-4c53-95af-e74c4890bb50">
<i>Zaire ebolavirus</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Zaire ebolavirus</i></b>
<b> infection (including newborns born to mothers RT-PCR positive for <i>Z. ebolavirus</i> infection):</b> IV: 50 mg/kg each of atoltivimab, maftivimab, and odesivimab as a single dose.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F54990598"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="798ca1a5-e33d-4c53-95af-e74c4890bb50">
<i>Zaire ebolavirus</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Zaire ebolavirus</i></b>
<b> infection:</b> Infants, Children, and Adolescents: IV: 50 mg/kg each of atoltivimab, maftivimab, and odesivimab as a single dose.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F54990599"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F54990600"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F54990574"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="129813" href="/d/html/129813.html" rel="external">see "Atoltivimab, maftivimab, and odesivimab (United States: Available via manufacturer expanded access or public health distribution): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="798ca1a5-e33d-4c53-95af-e74c4890bb50">
<i>Zaire ebolavirus</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>
<i>Zaire ebolavirus</i> infection:</b>
<b>IV:</b> 50 mg/kg <b>each </b>of atoltivimab, maftivimab, and odesivimab as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31774950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31774950'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F54990576"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F54990577"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F54962515"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (15%), tachycardia (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum potassium (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (11%), vomiting (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (39%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Tachypnea (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (54%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium (9%), decreased serum sodium (7%), increased serum sodium (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hypoxia (10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction</p></div>
<div class="block coi drugH1Div" id="F54950873"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F54990566"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including life-threatening infusion-related reactions, have been reported during and after receipt of atoltivimab, maftivimab, and odesivimab. Monitor for signs and symptoms such as fever, chills, and hypotension. May slow or interrupt infusion for any signs of infusion-related reaction or other adverse effects; immediately discontinue for severe or life-threatening hypersensitivity reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Avoid concurrent administration of a live vaccine during treatment with atoltivimab, maftivimab, and odesivimab.</p></div>
<div class="block prod-avail drugH1Div" id="F54950867"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Inmazeb: FDA approved October 2020. Product will not be commercially available; will only be distributed for a public health emergency in the US.</p></div>
<div class="block accres drugH1Div" id="F54990563"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Regeneron will provide atoltivimab, maftivimab, and odesivimab in response to outbreaks in the Democratic Republic of the Congo through the Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) protocol for compassionate use and is actively working with non-governmental agencies to ensure continued access to atoltivimab, maftivimab, and odesivimab in low- and middle-income countries. See inmazeb.com for more information.</p></div>
<div class="block admp drugH1Div" id="F54990614"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Must be diluted prior to administration. Allow diluted infusion to reach room temperature prior to administration; preparations diluted with D5W may be infused at temperatures up to 35°C (95°F), if temperature is &gt;25°C (77°F) administer immediately after preparation. Administer through an IV line containing a 0.2-micron filter. Infusion time is based on patient weight. Slow or interrupt infusion if the patient develops any signs of infusion-associated events (eg, hypotension, chills, fever elevation) or other adverse events; if severe or life-threatening hypersensitivity reactions occur, immediately discontinue infusion and provide emergency care.</p>
<p style="text-indent:-2em;margin-left:2em;">Infusion duration based on patient weight:</p>
<p style="text-indent:-2em;margin-left:4em;">0.5 to &lt;2 kg: Infuse over 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">2 to &lt;16 kg: Infuse over 3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">16 to &lt;150 kg: Infuse over 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">≥150 kg: Infuse over 4 hours.</p></div>
<div class="block adm drugH1Div" id="F54990578"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Allow diluted infusion solution to come to room temperature prior to administration; preparations diluted with D5W may be infused at temperatures up to 35°C (95°F); if temperature is &gt;25°C (&gt;77°F) administer immediately after preparation. Administer IV with 0.2-micron filter. Infusion rate is based on total volume: for 250 mL to 1 L, infuse over 2 hours; for 2 L, infuse over 4 hours. May slow or interrupt infusion for signs of infusion-associated events or other adverse events.</p></div>
<div class="block sts drugH1Div" id="F54990568"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to dilution: Store intact vials at 2°C to 8°C (36°F to 46°F). Protect from light; do not freeze or shake.</p>
<p style="text-indent:-2em;margin-left:2em;">After dilution:</p>
<p style="text-indent:-2em;margin-left:4em;">Diluted with NS: Store at room temperature up to 25°C (77°F) for no more than 8 hours or at 2°C to 8°C (36°F to 46°F) for no more than 24 hours. Do not freeze.</p>
<p style="text-indent:-2em;margin-left:4em;">Diluted with D5W: Store at room temperature up to 25°C (77°F) for no more than 4 hours or at 2°C to 8°C (36°F to 46°F) for no more than 24 hours. Do not freeze.</p>
<p style="text-indent:-2em;margin-left:4em;">Diluted with LR: Store at room temperature up to 25°C (77°F) or at 2°C to 8°C (36°F to 46°F) for no more than 4 hours. Do not freeze.</p></div>
<div class="block usep drugH1Div" id="F54962413"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of infection caused by <i>Zaire ebolavirus</i> (FDA approved in all ages).</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Efficacy not established for other species of the <i>Ebolavirus</i> and <i>Marburgvirus </i>genera.</p></div>
<div class="block cyt drugH1Div" id="F54992675"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F54992672"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ebola Zaire Vaccine (Live): Ebola-Directed Monoclonal Antibodies may diminish the therapeutic effect of Ebola Zaire Vaccine (Live).  Management: Wait several months (3 to 6 months, and up to 11 months) after use of Ebola-directed antibodies before administering the live Ebola Zaire vaccine. Repeat vaccination may be required if antibody therapy and vaccination cannot be adequately separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F54990564"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Atoltivimab, maftivimab, and odesivimab are humanized IgG1κ monoclonal antibodies and would be expected to cross the placenta. Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, newborn birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">A limited number of pregnant patients were included in a study that included treatment with atoltivimab, maftivimab, and odesivimab (Mulangu 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Following maternal infection, the Ebola virus can be detected in maternal body fluids and transmitted to the fetus. Maternal Ebola infection carries a high rate of mortality for both the fetus and the mother. Maternal Ebola virus infection typically results in miscarriage, stillbirth, and maternal and/or neonatal death (Olgun 2018). Treatment with atoltivimab/maftivimab/odesivimab should not be withheld due to pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Pregnant health care providers should not care for patients with Ebola virus disease (CDC 2018).</p></div>
<div class="block mopp drugH1Div" id="F54990619"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity or infusion-related reactions (eg, hypotension, chills, elevation of fever) during and following infusion.</p></div>
<div class="block pha drugH1Div" id="F54990570"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Atoltivimab, maftivimab, and odesivimab is an antiviral drug combination of 3 recombinant human IgG1κ monoclonal antibodies, each targeting the <i>Zaire ebolavirus</i> glycoprotein, which mediates viral attachment and host membrane fusion. Atoltivimab, maftivimab, and odesivimab can bind to the glycoprotein simultaneously. Maftivimab is a neutralizing antibody that blocks viral entry into host cells. Odesivimab is a non-neutralizing antibody that induces antibody-dependent effector function through FcyRIIIa signaling when bound to target; odesivimab also binds to soluble <i>Zaire ebolavirus</i> glycoprotein. Atoltivimab combines both neutralization and FcyRIIIa signaling activities.</p></div>
<div class="block phk drugH1Div" id="F54990571"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Mean V<sub>d</sub>, steady state: Atoltivimab: 58.2 mL/kg; Maftivimab: 57.6 mL/kg; Odesivimab: 56 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Atoltivimab: 21.2 days; Maftivimab: 22.3 days; Odesivimab: 25.3 days.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control (CDC). Centers for Disease Control and Prevention guidance for screening and caring for pregnant women with Ebola virus disease for healthcare providers in U.S. hospitals. <a href="https://www.cdc.gov/vhf/ebola/clinicians/evd/pregnant-women.html" target="_blank">https://www.cdc.gov/vhf/ebola/clinicians/evd/pregnant-women.html</a>. Updated May 30, 2018. Accessed January 7, 2021.</div>
</li>
<li>
<div class="reference">
                  Inmazeb (atoltivimab, maftivimab, and odesivimab) [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31774950">
<a name="31774950"></a>Mulangu S, Dodd LE, Davey RT Jr, et al; PALM Consortium Study Team. A randomized, controlled trial of ebola virus disease therapeutics. <i>N Engl J Med</i>. 2019;381(24):2293-2303. doi:10.1056/NEJMoa1910993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atoltivimab-maftivimab-and-odesivimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-pediatric-drug-information/abstract-text/31774950/pubmed" id="31774950" target="_blank">31774950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29384053">
<a name="29384053"></a>Olgun NS. Viral infections in pregnancy: a focus on Ebola virus. <i>Curr Pharm Des</i>. 2018;24(9):993-998. doi:10.2174/1381612824666180130121946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atoltivimab-maftivimab-and-odesivimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-pediatric-drug-information/abstract-text/29384053/pubmed" id="29384053" target="_blank">29384053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies.<i> Clin Dev</i>
<i>Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atoltivimab-maftivimab-and-odesivimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies.<i> Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atoltivimab-maftivimab-and-odesivimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32091684">
<a name="32091684"></a>World Health Organization (WHO). Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease. https://apps.who.int/iris/bitstream/handle/10665/330851/9789240001381-eng.pdf?ua=1. Published February 2020. Accessed January 28, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atoltivimab-maftivimab-and-odesivimab-united-states-available-via-manufacturer-expanded-access-or-public-health-distribution-pediatric-drug-information/abstract-text/32091684/pubmed" id="32091684" target="_blank">32091684</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 129868 Version 25.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
